Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate
Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate
Vanda Pharma 2024年第一季度GAAP每股收益（0.07）未达到预期的0.05美元，销售额为4,7462万美元，低于4,850万美元的预期
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. The company reported quarterly sales of $47.462 million which missed the analyst consensus estimate of $48.500 million by 2.14 percent. This is a 24.06 percent decrease over sales of $62.498 million the same period last year.
万达制药（纳斯达克股票代码：VNDA）公布的季度每股亏损为0.07美元，比分析师普遍预期的0.05美元低240％。该公司公布的季度销售额为4,7462万美元，比分析师普遍预期的4,850亿美元低2.14％。这比去年同期的6,249.8万美元的销售额下降了24.06％。